Determination of phage susceptibility as a clinical diagnostic tool : A routine perspective
Copyright © 2022 Daubie, Chalhoub, Blasdel, Dahma, Merabishvili, Glonti, De Vos, Quintens, Pirnay, Hallin and Vandenberg..
As the global burden of disease caused by multidrug resistant bacteria is a major source of concern, credible clinical alternatives to antibiotic therapy, such as personalized phage therapy, are actively explored. Although phage therapy has been used for more than a century, the issue of an easy to implement diagnostic tool for determining phage susceptibility that meets current routine clinical needs is still open. In this Review, we summarize the existing methods used for determining phage activity on bacteria, including the three reference methods: the spot test, the double agar overlay plaque assay, and the Appelmans method. The first two methods rely on the principle of challenging the overnight growth of a lawn of bacteria in an agar matrix to a known relative phage to bacteria concentration and represent good screening tools to determine if the tested phage can be used for a "passive" and or "active" treatment. Beside these methods, several techniques, based on "real-time" growth kinetics assays (GKA) have been developed or are under development. They all monitor the growth of clinical isolates in the presence of phages, but use various detection methods, from classical optical density to more sophisticated techniques such as computer-assisted imagery, flow-cytometry, quantitative real-time polymerase chain reaction (qPCR) or metabolic indicators. Practical considerations as well as information provided about phage activity are reviewed for each technique. Finally, we also discuss the analytical and interpretative requirements for the implementation of a phage susceptibility testing tool in routine clinical microbiology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in cellular and infection microbiology - 12(2022) vom: 30., Seite 1000721 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Daubie, Valéry [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9002-18-0 |
|---|
| Anmerkungen: |
Date Completed 11.10.2022 Date Revised 12.10.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fcimb.2022.1000721 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347272185 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347272185 | ||
| 003 | DE-627 | ||
| 005 | 20231226033437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcimb.2022.1000721 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347272185 | ||
| 035 | |a (NLM)36211951 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Daubie, Valéry |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Determination of phage susceptibility as a clinical diagnostic tool |b A routine perspective |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2022 | ||
| 500 | |a Date Revised 12.10.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Daubie, Chalhoub, Blasdel, Dahma, Merabishvili, Glonti, De Vos, Quintens, Pirnay, Hallin and Vandenberg. | ||
| 520 | |a As the global burden of disease caused by multidrug resistant bacteria is a major source of concern, credible clinical alternatives to antibiotic therapy, such as personalized phage therapy, are actively explored. Although phage therapy has been used for more than a century, the issue of an easy to implement diagnostic tool for determining phage susceptibility that meets current routine clinical needs is still open. In this Review, we summarize the existing methods used for determining phage activity on bacteria, including the three reference methods: the spot test, the double agar overlay plaque assay, and the Appelmans method. The first two methods rely on the principle of challenging the overnight growth of a lawn of bacteria in an agar matrix to a known relative phage to bacteria concentration and represent good screening tools to determine if the tested phage can be used for a "passive" and or "active" treatment. Beside these methods, several techniques, based on "real-time" growth kinetics assays (GKA) have been developed or are under development. They all monitor the growth of clinical isolates in the presence of phages, but use various detection methods, from classical optical density to more sophisticated techniques such as computer-assisted imagery, flow-cytometry, quantitative real-time polymerase chain reaction (qPCR) or metabolic indicators. Practical considerations as well as information provided about phage activity are reviewed for each technique. Finally, we also discuss the analytical and interpretative requirements for the implementation of a phage susceptibility testing tool in routine clinical microbiology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a clinical microbiology | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a personalized medicine | |
| 650 | 4 | |a phage (bacteriophage) | |
| 650 | 4 | |a susceptibility | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Agar |2 NLM | |
| 650 | 7 | |a 9002-18-0 |2 NLM | |
| 700 | 1 | |a Chalhoub, Houssein |e verfasserin |4 aut | |
| 700 | 1 | |a Blasdel, Bob |e verfasserin |4 aut | |
| 700 | 1 | |a Dahma, Hafid |e verfasserin |4 aut | |
| 700 | 1 | |a Merabishvili, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Glonti, Tea |e verfasserin |4 aut | |
| 700 | 1 | |a De Vos, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Quintens, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Pirnay, Jean-Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Hallin, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Vandenberg, Olivier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cellular and infection microbiology |d 2011 |g 12(2022) vom: 30., Seite 1000721 |w (DE-627)NLM220414289 |x 2235-2988 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g day:30 |g pages:1000721 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcimb.2022.1000721 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |b 30 |h 1000721 | ||